Science News
from research organizations

Unique gene signature predicts potentially lethal prostate cancers

Date:
January 10, 2017
Source:
Roswell Park Cancer Institute
Summary:
Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of scientists has identified an 11-gene signature unique to advanced recurrent prostate cancer that they believe will help to identify these aggressive and potentially fatal prostate cancers sooner.
Share:
FULL STORY

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of scientists led by Irwin Gelman, PhD, Professor of Oncology in the Department of Cancer Genetics at Roswell Park Cancer Institute, has identified an 11-gene signature unique to advanced recurrent prostate cancer that they believe will help to identify these aggressive and potentially fatal prostate cancers sooner. The findings have been published online ahead of print in the journal Oncotarget.

For this analysis, Roswell Park researchers measured genes that were specifically induced in human prostate cancer cells by the Src oncogene, a known driver of metastatic progression and recurrence in this disease. They compared these genes to genes that are only active in prostate cancer cells and tumors that have recurred after androgen-deprivation therapy. Through this process, the scientists identified an 11-gene signature that is unique to advanced recurrent prostate cancer.

The researchers also characterized how the Src oncogene drives recurrent prostate cancer through direct activation of the androgen receptor, thereby allowing it to function even after therapy has removed detectable levels of serum androgens. They found that this 11-gene pattern is a biomarker that correlates with a more rapid progress to metastasis and decreased overall survival from prostate cancer.

"This study adds to our understanding of why some men experience metastatic progressive disease after androgen-deprivation therapy," says Dr. Gelman. "Our data strengthen the idea that combining therapies that inhibit the oncogene Src with those that constrain the androgen receptor may help prevent recurrence of aggressive, lethal prostate cancer."


Story Source:

Materials provided by Roswell Park Cancer Institute. Note: Content may be edited for style and length.


Journal Reference:

  1. Indranil Chattopadhyay, Jianmin Wang, Maochun Qin, Lingqiu Gao, Renae Holtz, Robert L. Vessella, Robert W. Leach, Irwin H. Gelman. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures. Oncotarget, 2016; DOI: 10.18632/oncotarget.14401

Cite This Page:

Roswell Park Cancer Institute. "Unique gene signature predicts potentially lethal prostate cancers." ScienceDaily. ScienceDaily, 10 January 2017. <www.sciencedaily.com/releases/2017/01/170110154116.htm>.
Roswell Park Cancer Institute. (2017, January 10). Unique gene signature predicts potentially lethal prostate cancers. ScienceDaily. Retrieved May 26, 2017 from www.sciencedaily.com/releases/2017/01/170110154116.htm
Roswell Park Cancer Institute. "Unique gene signature predicts potentially lethal prostate cancers." ScienceDaily. www.sciencedaily.com/releases/2017/01/170110154116.htm (accessed May 26, 2017).

RELATED STORIES